Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?

Key Takeaways NVO is investing in rare disease treatments to diversify beyond its GLP-1-based therapies. Recent EU approval of Alhemo and late-stage Mim8 study results reflect NVO's hemophilia pipeline progress. NVO also plans 2025 filings for semaglutide in MASH, aiming to expand its metabolic disease footprint.Novo Nordisk (NVO) has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and Oze ...